 Investors had a field day with Greenwich LifeSciences on Wednesday after the tiny biotech company skyrocketed as much as 2,941 on encouraging phase 2b data for its breast cancer immunotherapy treatment, GP2. On Tuesday, shares of Greenwich LifeSciences closed at 5.20. The stock proceeded to trade as high as 158.07 just before 3 p.m. on Wednesday. The market value of Greenwich soared to more than 1.5 billion at intraday highs, up from just 62 million the prior day. 